Teva Pharmaceutical Industries Limited

NYSE:TEVA Stock Report

Market Cap: US$20.0b

Teva Pharmaceutical Industries Dividends and Buybacks

Dividend criteria checks 0/6

Teva Pharmaceutical Industries does not currently pay a dividend.

Key information

0%

Dividend yield

n/a

Buyback Yield

Total Shareholder Yieldn/a
Future Dividend Yield0%
Dividend Growthn/a
Next dividend pay daten/a
Ex dividend daten/a
Dividend per shareUS$0.340
Payout ratio0%

Recent dividend and buyback updates

No updates

Recent updates

Teva: Becoming Increasingly Solid, But No Longer Undervalued

Dec 04

Why Investors Shouldn't Be Surprised By Teva Pharmaceutical Industries Limited's (NYSE:TEVA) Low P/S

Nov 17
Why Investors Shouldn't Be Surprised By Teva Pharmaceutical Industries Limited's (NYSE:TEVA) Low P/S

Teva: Great Time To Buy Leading Generic Drugmaker With Growth Indicators And Lower Debt

Oct 23

Is Teva Pharmaceutical Industries (NYSE:TEVA) Using Too Much Debt?

Oct 21
Is Teva Pharmaceutical Industries (NYSE:TEVA) Using Too Much Debt?

Cheap Teva Stock Should Reward Patient Investors

Sep 09

Teva's Transformation: From Generics Leader To Branded Drug Innovator

Aug 14

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year

Aug 02
Teva Pharmaceutical Industries Limited (NYSE:TEVA) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year

Teva's Q2 Outlook: Key Developments In Biosimilars And Pipeline Drugs

Jul 26

Is Teva Pharmaceutical Industries (NYSE:TEVA) A Risky Investment?

Jul 12
Is Teva Pharmaceutical Industries (NYSE:TEVA) A Risky Investment?

Teva Pharmaceutical: Buy This Bargain Before It's Gone

Jun 07

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Stock Catapults 27% Though Its Price And Business Still Lag The Industry

May 14
Teva Pharmaceutical Industries Limited (NYSE:TEVA) Stock Catapults 27% Though Its Price And Business Still Lag The Industry

Teva: Sustained Revenue Growth Amid Financial Strain (Rating Downgrade)

May 09

Teva Pharmaceutical Industries (NYSE:TEVA) Has A Somewhat Strained Balance Sheet

Mar 26
Teva Pharmaceutical Industries (NYSE:TEVA) Has A Somewhat Strained Balance Sheet

Teva Pharmaceutical Industries: Potential Outweighs Concerns

Mar 25

Teva And Alvotech: Simlandi Approval Opens New Generic Market Opportunities

Feb 26

A Review Of Teva's Prospects

Feb 15

Teva Pharmaceutical Industries Limited's (NYSE:TEVA) Business And Shares Still Trailing The Industry

Jan 07
Teva Pharmaceutical Industries Limited's (NYSE:TEVA) Business And Shares Still Trailing The Industry

Teva: 4 Key Drivers For A 2024 Revival (Upgraded Rating)

Dec 08

Teva: Deeply Undervalued FCF Machine

Nov 20

Teva: Focus On Innovation And Growth Means The Times They Are A Changing

Sep 14

The Mighty Teva Pharmaceutical: Unveiling A Bullish Scenario You Must Consider

Aug 26

Teva Q2 Earnings: Austedo And Anda Growth Impress, But Challenges Remain

Aug 02

Teva Pharmaceutical: Lacking Capabilities For Strategic Investments

Jul 20

Teva Pharmaceutical: New Growth Plan Could Restore Investor Confidence

Jun 15

What To Expect From Teva Pharmaceutical In 2023 With A New CEO

Feb 15

Can Teva Pharmaceutical's Q4 results bring positive surprise?

Feb 07

Teva Pharmaceutical: Stuck In A Cycle Of Hope And Disappointment

Jan 19

Tamiflu supplies released from national stockpile as nationwide shortage persists

Jan 12

Teva Pharmaceutical: 2023 Could Finally Be The Stock's Breakout Year

Dec 28

Federal appeals court temporarily blocks generics of Vanda's Hetlioz by Teva, Apotex

Dec 16

Boston jury orders Lilly to pay $176.5M to Teva in migraine drug patent suit

Nov 10

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if TEVA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if TEVA's dividend payments have been increasing.


Dividend Yield vs Market

Teva Pharmaceutical Industries Dividend Yield vs Market
How does TEVA dividend yield compare to the market?
SegmentDividend Yield
Company (TEVA)0%
Market Bottom 25% (US)1.4%
Market Top 25% (US)4.3%
Industry Average (Pharmaceuticals)2.4%
Analyst forecast (TEVA) (up to 3 years)0%

Notable Dividend: Unable to evaluate TEVA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate TEVA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Earnings Payout to Shareholders

Earnings Coverage: TEVA is not paying a notable dividend for the US market.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as TEVA has not reported any payouts.


Discover strong dividend paying companies